At a glance
- Originator Gilead Sciences; GlaxoSmithKline
- Developer Gilead Sciences; GSK
- Class Antineoplastics
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Nov 1999 Investigation in Cancer in USA (Unknown route)
- 21 Sep 1998 No-Development-Reported for Cancer in USA (Unknown route)
- 21 Nov 1996 Preclinical development for Cancer in USA (Unknown route)